We used KC mice expressing the mutation of Kras (KrasG12D) in pancreatic progenitor cells and progressing from a healthy condition to different grades of PanIN (PanIN‐1A–1B–2–3) (Hingorani et al, 2003; Cappello et al, 2013) and KPC mice, carrying KrasG12D/+ and p53R172H/+ mutations and developing PanINs that ultimately progresses to overt carcinoma (Hingorani et al, 2005) to study the importance of the selected biomarkers during PDAC induction. The gene discussed is KRAS; the disease is carcinoma.